Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

SHARE CAPITAL

v3.21.2
SHARE CAPITAL
6 Months Ended
Jun. 30, 2021
Share Capital [Abstract]  
SHARE CAPITAL

9.SHARE CAPITAL

(a) Authorized: unlimited number of common shares, no par value

Issued: 110,927,690 (December 31, 2020: 83,184,843)

Exercise prices of units, warrants, options and RSUs, are presented in US dollars unless otherwise noted.

Aspire Agreement

During Q2, 2021, the Company issued 1,400,000 Common Shares to Aspire Capital Fund, LLC for proceeds of $2,524 pursuant to the December 23, 2019 common share purchase agreement.

January 2021 Equity Offering

On January 26, 2021, the Company closed an offering of 7,419,354 units of the Company (“January 2021 Units) sold on a “bought deal” basis, at a price of $1.55 per January 2021 Unit for aggregate gross proceeds of $11,500 ($10,231 net of z13637share issuance costs). Each January 2021 Unit consists of one Common Share in the capital of the Company (each a “Common Share”) and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “January 2021 Warrant”). Each January 2021 Warrant is exercisable to acquire one Common Share at an exercise price of $2.00 per share until January 26, 2026. In connection with the January 2021 Offering, the Company issued 518,234 broker warrants, each exercisable at $1.9375 until January 26, 2023 treated as share issuance costs. January 2021 Warrants and broker warrants associated with this raise qualified as equity classification – see Note 9(c).

February 2021 Equity Offering

On February 24, 2021, the Company closed an offering of 9,585,250 units of the Company (“February 2021 Units”) at a price of $2.40 per February 2021 Unit for aggregate gross proceeds of $23,005 ($21,093 net of share issuance costs). Each February 2021 Unit consists of one Common share and one half (1/2) of one Common Share purchase warrant (each whole warrant, a “February 2021 Warrant”). Each February 2021 Warrant is exercisable to acquire one Common Share at an exercise price of $3.00 per share until February 24, 2023. In connection with the February 2021 Offering, the Company issued 670,967 broker warrants exercisable at $3.00 until February 24, 2023 treated as share issuance costs. February 2021 Warrants and broker warrants associated with this raise qualified as equity classification – see Note 9(c).

(b)Stock-Based Compensation

Titan has reserved and set aside up to 15% of the issued and outstanding Common Shares for the granting of stock options and restricted share units to eligible employees, officers, consultants, and advisors. The Company’s compensation plan includes the Share Unit Plan (the “SU Plan”), the Deferred Unit Plan (the “DSU Plan”), the Stock Option Plan (the “Option Plan”), collectively the “Compensation Plan”. At June 30, 2021, 9,328,028 Common Shares were remaining available to issue under the Compensation Plan.

Common shares outstanding

110,927,690

Available for issuance – 15% of common share outstanding

16,639,154

Reserved for stock options

(5,396,145

)

Reserved for RSUs

(1,914,981

)

Remainder available to reserve for future grants

9,328,028

 

image provided by client

SECOND QUARTER 2021

 9


TITAN MEDICAL INC.

Notes to the Condensed Interim Consolidated Financial Statements

(Unaudited)

For the Quarter Ended June 30, 2021

(In thousands of US dollars except per share amounts and as otherwise indicated.)

During Q2, 2021, the Company granted 821,124 stock options and 387,121 RSUs to Directors, Officers and Employees. The stock-based compensation expense is presented in the General and administrative expense as follows:

Three Months Ended

Six Months Ended

June 30, 2021

June 30, 2020

June 30, 2021

June 30, 2020

 

Options

$

775

$

206

$

1,202

$

435

RSUs

654

-

996

-

Stock-based compensation expense

$

1,429

$

206

$

2,198

$

435

(i)Options

A summary of the status of the Company’s outstanding stock options as of June 30, 2021, is presented in the following table:

Three Months Ended

June 30, 2021

Six Months Ended

June 30, 2021

Stock options outstanding

Number

stock

options

Weighted

Average

Exercise

Price

Number of

stock

options

Weighted

Average

Exercise

Price

Balance, Opening

4,685,021

$

1.94

2,923,770

$

1.77

Granted

821,124

1.87

2,622,386

2.10

Exercised

-

-

(19,568

)

0.73

Expired

-

-

(9,810

)

3.66

Cancelled/ forfeited

(110,000

)

1.31

(120,633

)

1.44

Balance, June 30, 2021

5,396,145

$

1.94

5,396,145

$

1.94

 

image provided by client

SECOND QUARTER 2021

 10


TITAN MEDICAL INC.

Notes to the Condensed Interim Consolidated Financial Statements

(Unaudited)

For the Quarter Ended June 30, 2021

(In thousands of US dollars except per share amounts and as otherwise indicated.)

During Q2, 2021, the company granted 821,124 stock options with the terms outlined below:

Grant date / recipient

Number of

options

Exercise

price

Vesting conditions

Contractual

life of options

June 10, 2021, options A

340,000

$1.87

Options vest as to ¼ of the total number of options granted on the first anniversary of the grant date, and monthly for the remaining ¾ in equal amounts

7 years

June 10, 2021, options B

471,500

$1.87

Options vest as to ¼ of the total number of options granted on each annual anniversary of the grant date, beginning on the first year anniversary of the grant date

7 years

June 10, 2021, options C

9,624

$1.87

Options vest immediately

7 years

Total options granted in Q2, 2021

821,124

(ii)Restricted Share Units

A summary of the status of the Company’s outstanding RSUs as of June 30, 2021, is presented in the following table:

Three Months Ended

June 30, 2021

Six Months Ended

June 30, 2021

Number

of RSUs

Weighted

Average

Exercise

Price

Number

of RSUs

Weighted

Average

Exercise

Price

Balance, Opening

1,527,860

$

2.34

-

$

-

Granted

387,121

1.87

1,914,981

2.24

Balance, June 30, 2021

1,914,981

$

2.24

1,914,981

$

2.24

During the quarter, the Company granted 387,121 RSUs pursuant to its Share Unit Plan. RSUs are notional share units exchangeable for common shares of the Company upon vesting.

 

image provided by client

SEOND QUARTER 2021

 11


TITAN MEDICAL INC.

Notes to the Condensed Interim Consolidated Financial Statements

(Unaudited)

For the Quarter Ended June 30, 2021

(In thousands of US dollars except per share amounts and as otherwise indicated.)

Grant date / recipient

Vesting conditions

Number of RSUs

June 10, 2021 RSUs A

RSUs vest as to ¼ of the total number of units granted, on each of four anniversaries from the grant date

210,000

June 10, 2021 RSUs B

RSUs vest on the earliest of the Company’s next annual general meeting of the shareholder’s and 12 months from the grant date

176,468

June 10 2021 RSUs C

RSUs vested immediately

653

Total RSUs granted in Q2, 2021

387,121

The RSU grants were fair valued using the closing share price of the trading date prior to the June 10, 2021 grant date.

(c)Contributed Surplus–Warrant Reserve

As at June 30, 2021, the Company has 9,912,633 equity warrants that are issued, outstanding and exercisable (December 31, 2020: 2,131,716). These equity warrants expire between January 26, 2023, and November 6, 2025, (December 31, 2020: equity warrants had expiry dates between April 12, 2020, and November 6, 2025). Due to the equity classification, the equity warrants are not revalued each reporting period.

Equity warrant

units

Average

exercise price

$

Warrant Reserve

$

Balance at January 1, 2021

2,131,716

1.72

1,671

January 2021 Equity Offering

3,709,677

2.00

3,164

January 2021 Equity Offering-broker warrants

518,234

1.94

1,384

February 2021 Equity Offering

4,792,625

3.00

5,928

February 2021 Equity Offering-broker warrants

670,967

3.00

1,238

Exercised

(1,318,675

)

(1.51

)

-

Expired

(591,911

)

(3.40

)

-

Equity warrants as at June 30, 2021

9,912,633

2.67

13,385